Mucinous adenocarcinoma

Summary

Mucinous adenocarcinoma (MONDO:0004957) is a disease (an umbrella term covering 17 Mondo subtypes) and 6 clinical trials. Molecularly, CD74::NRG1 Fusion confers sensitivity to Afatinib in Mucinous Adenocarcinoma (CIViC Level C); 3 further subtype–drug associations are mapped below. Top therapeutic interventions include bevacizumab, bromelains, and gemcitabine hydrochloride. A subtype of adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 17 Mondo subtypes
• Clinical trials: 6
• Precision-medicine evidence (CIViC): 4 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mucinous adenocarcinoma
Mondo ID	MONDO:0004957
EFO	EFO:0000197
MeSH	D002288
DOID	DOID:3030
ICD-11	529352875
NCIT	C26712
UMLS	C0007130
MedGen	2844
Is cancer (heuristic)	no

Also known as: adenocarcinoma, mucinous, malignant · CEMU · colloid adenocarcinoma · colloid carcinoma · gelatinous adenocarcinoma · gelatinous carcinoma · mucin-producing adenocarcinoma (morphologic abnormality) · mucinous adenocarcinoma · mucinous carcinoma · mucinuos carcinoma · mucoid adenocarcinoma · mucoid carcinoma · mucous adenocarcinoma · mucous carcinoma

Disease family

This is a subtype of adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › mucinous adenocarcinoma

Related subtypes (63): epididymal adenocarcinoma, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, ethmoid sinus adenocarcinoma, lacrimal gland adenocarcinoma, papillary adenocarcinoma, fallopian tube adenocarcinoma, bladder adenocarcinoma, ovarian adenocarcinoma, trabecular adenocarcinoma, middle ear adenocarcinoma, bile duct adenocarcinoma, granular cell carcinoma, small intestine adenocarcinoma, urethra adenocarcinoma, villous adenocarcinoma, thymus gland adenocarcinoma, nasal cavity adenocarcinoma, ureter adenocarcinoma, adenocarcinoma in situ, gastroesophageal junction adenocarcinoma, maxillary sinus adenocarcinoma, acinar cell carcinoma, adenoid cystic carcinoma, breast adenocarcinoma, clear cell adenocarcinoma, colorectal adenocarcinoma, endometrioid adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, renal cell carcinoma, signet ring cell carcinoma, cervical adenocarcinoma, serous adenocarcinoma, endometrium adenocarcinoma, sweat gland carcinoma, cystadenocarcinoma, tubular adenocarcinoma, mesonephric adenocarcinoma, scirrhous adenocarcinoma, pancreatic adenocarcinoma, follicular variant thyroid gland papillary carcinoma, gallbladder adenocarcinoma, hepatoid adenocarcinoma, intestinal type adenocarcinoma, micropapillary serous carcinoma, minor salivary gland adenocarcinoma, poorly differentiated thyroid gland carcinoma, salivary gland basal cell adenocarcinoma, submandibular gland adenocarcinoma, sebaceous adenocarcinoma, hepatocellular carcinoma, parathyroid gland carcinoma, pituitary adenocarcinoma, vaginal adenocarcinoma, Paget disease, diffuse type adenocarcinoma, vulvar adenocarcinoma, thyroid gland adenocarcinoma, gastroesophageal adenocarcinoma, adenoacanthoma

Subtypes (17): breast mucinous carcinoma, extrahepatic bile duct mucinous adenocarcinoma, cervical mucinous adenocarcinoma, fallopian tube mucinous adenocarcinoma, endometrial mucinous adenocarcinoma, rectum mucinous adenocarcinoma, mucoepidermoid carcinoma, gallbladder mucinous adenocarcinoma, colloid carcinoma of the pancreas, colon mucinous adenocarcinoma, ovarian mucinous adenocarcinoma, mucinous cystadenocarcinoma, acinar prostate mucinous adenocarcinoma, mucinous gastric adenocarcinoma, lung colloid adenocarcinoma, mucinous pancreas adenocarcinoma, salivary gland mucinous adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00565851	PHASE3	ACTIVE_NOT_RECRUITING	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT05504252	PHASE2	ACTIVE_NOT_RECRUITING	METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
NCT03976973	PHASE2	UNKNOWN	BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
NCT04088786	PHASE1	COMPLETED	Phase I Trial HIPEC With Nal-irinotecan
NCT06182644	Not specified	UNKNOWN	Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1
BROMELAINS	4	1
GEMCITABINE HYDROCHLORIDE	4	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 4 predictive associations from 5 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
CD74::NRG1 Fusion	Afatinib	Sensitivity/Response	CIViC C	EID7490 +1
NRG1 Fusion	Anti-HER3 Monoclonal Antibody GSK2849330	Sensitivity/Response	CIViC C	EID6095
NRG1 Fusion	Afatinib	Sensitivity/Response	CIViC C	EID6096
SLC3A2::NRG1 Fusion	Erlotinib + Lumretuzumab	Sensitivity/Response	CIViC C	EID7495